ArticleFrontiers in nutrition2025
Evaluation of the antidyslipidemic and nephroprotective effect of methanolic seed extract of
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Phytochemical insights and pharmacological advances of Lepidium sativum L. (garden cress): bridging traditional medicine and evidence-based therapeutics.Journal, genetic engineering & biotechnology · 2026Review
- Postbiotics fromNutrients · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Currently, there is dramatic change in dietary habits. Consumption of energy dense foods are becoming common practice globally. Increased consumption of energy dense foods are main cause of disorder on lipid metabolism and kidney function, which are primary risk factors for many chronic diseases. Thus, this study aims to evaluate antidyslipidemic and nephroprotective effect of methanolic seed extract of Methods: The study carried out using 24 mice that grouped into four groups. G-I fed on normal mice pellets and distilled water. G- II fed on deep fried palm oil and distilled water. G-III and IV fed on deep fried palm oil and treated with MSELS of 200 and 400 mg/ kg/day, respectively. Each group treated per orally for 8 weeks. At the end of study, mice fasted overnight, anesthetized and blood taken by cardiac puncture for lipid profile and kidney parameters. Then, sacrificed by cervical dislocation, liver and kidney tissues taken for histopathology investigation. Result and Discussion: The serum total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), and triglyceride (TG) levels decreased while high density lipoprotein cholesterol (HDL-C) increased significantly in G- IV only whereas serum LDL-C/HDL-C ratio and creatinine levels showed a significant decrement in both G- III and IV when compared with G- II. The serum blood urea nitrogen (BUN) and uric acid levels decreased in G- III and IV even though only serum uric acid value in G-IV decreased significantly when compared with G-II. Besides, G-IV showed significant reduction in liver weight as well as restoration of liver and kidney histopathology when compared with G- II than G-III. Conclusion: Based on the above results, MSELS showed better antidyslipidemic and nephroprotective effect on male mice treated with deep fried palm oil at the dose of 400 mg/kg/day of MSELS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.